TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32154636

Group type: EXPERIMENTAL
Intervention: Gilteritinib (120 mg once daily)
Number of subjects: 371

Group type: COMPARATOR
Intervention: Salvage chemotherapy
Number of subjects: 371
Study: 37644897

Group type: EXPERIMENTAL
Intervention: THC 10 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: THC 20 mg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 35089501

Group type: EXPERIMENTAL
Intervention: Parent Management Training combined with Coping Power Program (CPP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parent Management Training (PMT) only
Number of subjects: 0
Study: 33326356

Group type: EXPERIMENTAL
Intervention: ALIS+GBT (590 mg once-daily for 12 months)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: ALIS+GBT
Number of subjects: 163
Study: 32569757

Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS) active stimulation during year one
Number of subjects: 500

Group type: COMPARATOR
Intervention: Delayed stimulation after year one (Control)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS)
Number of subjects: 500
Study: 34325483

Group type: EXPERIMENTAL
Intervention: Withdrawal and early preventive medication (W+P)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Preventives with potential withdrawal therapy after 6 months (P+pW)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Withdrawal with delayed potential preventives (W+pP)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Overall treatment effect (all groups combined)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Chronic headache after 1 year
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Predictors of chronic headache
Number of subjects: 120
Study: 32252983

Group type: EXPERIMENTAL
Intervention: Telemedicine follow-up
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional follow-up
Number of subjects: 200
Study: 33221559

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 gm if body weight <90 kg, 1.5 g if body weight >90 kg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (5 ml of distilled water in 15 ml of 5% dextrose)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 32622904

Group type: EXPERIMENTAL
Intervention: Inspiratory loading (IL) of 41 cm H2O (∼30 % of maximal inspiratory pressure)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Inspiratory loading (IL)
Number of subjects: 10
Study: 37100921

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Remifentanil infusion
Number of subjects: 0
Study: 33486657

Group type: EXPERIMENTAL
Intervention: Immediate freezing after operation (Group 1)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Cooling to 5 °C for 24 hours before freezing (Group 2)
Number of subjects: 16
Study: 32610342

Group type: EXPERIMENTAL
Intervention: Early cord clamping (≤10 s)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Delayed cord clamping (≥180 s)
Number of subjects: 400
Study: 33053279

Group type: EXPERIMENTAL
Intervention: BNT162b2 (lipid nanoparticle-formulated, nucleoside-modified RNA vaccine candidate)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: BNT162b1 (lipid nanoparticle-formulated, nucleoside-modified RNA vaccine candidate)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study: 35907513

Group type: EXPERIMENTAL
Intervention: Metformin 500 mg by mouth 3 times a day for 30-36 months
Number of subjects: 83
Study: 32948827

Group type: EXPERIMENTAL
Intervention: bissap tablets (2 × 375 mg/day)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: bissap brew (10 g of calyx/day)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: kinkeliba tablets (2 × 200 mg/day)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: kinkeliba brew (10 g of leaves/day)
Number of subjects: 219

Group type: COMPARATOR
Intervention: captopril (2 × 50 mg/day)
Number of subjects: 219
Study: 35695316

Group type: EXPERIMENTAL
Intervention: Clinical-radiomics model
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Clinical-radiomics nomogram
Number of subjects: 522
Study: 33443933

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) administered before surgery and at various time points postoperatively.
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo administered before surgery and at various time points postoperatively.
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Oral TXA (1g) taken by healthy volunteers.
Number of subjects: 41
Study: 32943033

Group type: COMPARATOR
Intervention: High-risk group based on risk score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nomogram based on survival-related genes
Number of subjects: 0
Study: 35605268

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 8.75 mg and cetylpyridinium chloride 1.00 mg in the form of tablets for resorption
Number of subjects: 266

Group type: COMPARATOR
Intervention: Cetylpyridinium chloride 1.2 mg in the form of medicinal lozenges
Number of subjects: 266
Study: 34207221

Group type: EXPERIMENTAL
Intervention: High dairy product (HD) consumption (≥4 servings/day)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Adequate dairy product (AD) consumption (≤2 servings/day)
Number of subjects: 27
Study: 34368999

Group type: EXPERIMENTAL
Intervention: 1.1 GBq radioactive iodine (RAI) ablation
Number of subjects: 506

Group type: COMPARATOR
Intervention: 3.7 GBq radioactive iodine (RAI) ablation
Number of subjects: 506
Study: 32616022

Group type: EXPERIMENTAL
Intervention: Data linkage consent
Number of subjects: 9232

Group type: EXPERIMENTAL
Intervention: Successfully linked students
Number of subjects: 9232

Group type: COMPARATOR
Intervention: Mental health diagnoses
Number of subjects: 9232

Group type: COMPARATOR
Intervention: Specialist contacts
Number of subjects: 9232
Study: 36349428

Group type: EXPERIMENTAL
Intervention: fMRI neurofeedback (fMRI‐NF) of the right inferior frontal cortex (rIFC)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Sham fMRI neurofeedback
Number of subjects: 88
Study: 33406859

Group type: EXPERIMENTAL
Intervention: C. nebraskensis inoculation at V6 to V10 on susceptible hybrid
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: C. nebraskensis inoculation at V6 to V10 on moderately susceptible hybrid
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: C. nebraskensis inoculation on resistant hybrid
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Increase in R1 disease severity on susceptible hybrid
Number of subjects: 6

Group type: COMPARATOR
Intervention: Noninoculated control
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: C. nebraskensis inoculation at reproductive silk stage (R1)
Number of subjects: 6
Study: 32846782

Group type: EXPERIMENTAL
Intervention: 20 mg dexamethasone (4 mL) intravenously just after anesthesia and repeated at 24 hours after surgery
Number of subjects: 80

Group type: COMPARATOR
Intervention: 10 mg dexamethasone (2 mL) intravenously just after anesthesia and repeated at 24 hours after surgery
Number of subjects: 80
Study: 34175463

Group type: EXPERIMENTAL
Intervention: Liberal policy of preventive stoma (LPS)
Number of subjects: 363

Group type: COMPARATOR
Intervention: Restrictive policy of preventive stoma (RPS)
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Without stoma at RPS center
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: With stoma at RPS center
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Without stoma at LPS center
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: With stoma at LPS center
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Performing rectal sutures within 8 cm from the anal verge
Number of subjects: 363
Study: 33126534

Group type: EXPERIMENTAL
Intervention: Cynara scolymus (Cs) extract supplementation
Number of subjects: 54
Study: 35759976

Group type: EXPERIMENTAL
Intervention: Gentle Human Touch (GHT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 33648834

Group type: EXPERIMENTAL
Intervention: Sodium 4-phenylbutyrate (NaPB) high dose (4.3 g/m2) administered pre-breakfast
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sodium 4-phenylbutyrate (NaPB) low dose (1.4 g/m2) administered pre-breakfast
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sodium 4-phenylbutyrate (NaPB) administered post-breakfast (both doses)
Number of subjects: 20
Study: 32198642

Group type: EXPERIMENTAL
Intervention: Abiraterone (AA) with statin and vitamin D
Number of subjects: 0

Group type: COMPARATOR
Intervention: Abiraterone (AA) alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abiraterone (AA) plus statin plus vitamin D
Number of subjects: 0
Study: 35863990

Group type: EXPERIMENTAL
Intervention: Single CO2 laser treatment
Number of subjects: 119

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 119
Study: 33854307

Group type: EXPERIMENTAL
Intervention: High-Intensity Resistance Exercise Training (HIT-RT) for 18 months
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: High-Intensity Resistance Exercise Training (HIT-RT) followed by 6 months of detraining
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control Group (non-training)
Number of subjects: 43
Study: 34158598

Group type: EXPERIMENTAL
Intervention: Ribociclib plus endocrine therapy (RIB + ET)
Number of subjects: 818
Study: 35831046

Group type: EXPERIMENTAL
Intervention: Delayed consent after in‐person assessment for health data
Number of subjects: 2110

Group type: EXPERIMENTAL
Intervention: Concurrent consent during in‐person assessment for health data
Number of subjects: 2110

Group type: EXPERIMENTAL
Intervention: Delayed consent after in‐person assessment for education data
Number of subjects: 2110

Group type: EXPERIMENTAL
Intervention: Concurrent consent during in‐person assessment for education data
Number of subjects: 2110

Group type: EXPERIMENTAL
Intervention: Combined consent for health and education data
Number of subjects: 2110

Group type: EXPERIMENTAL
Intervention: Separate consent for health and education data
Number of subjects: 2110

Group type: COMPARATOR
Intervention: Control groups with a baseline consent rate of 90%
Number of subjects: 2110
Study: 33010045

Group type: EXPERIMENTAL
Intervention: Mentalization‐Based Treatment (MBT)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 75
Study: 35284808

Group type: EXPERIMENTAL
Intervention: 1 µg
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: 1 µg + CpG1018
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: 3 µg
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: 3 µg + CpG1018
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: 10 µg
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 33156761

Group type: EXPERIMENTAL
Intervention: Xpert® MTB/RIF
Number of subjects: 72985

Group type: EXPERIMENTAL
Intervention: Chest Radiography (CXR)
Number of subjects: 72985
Study: 35848978

Group type: EXPERIMENTAL
Intervention: Auricular acupressure with magnetic plates (study group)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Auricular acupressure without magnetic plates (placebo group)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Routine post cesarean pain management (control group)
Number of subjects: 195
Study: 34011035

Group type: EXPERIMENTAL
Intervention: Bailing Capsule (BC) combined with α-ketoacid tablets (KA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: BC-simulation combined with α-ketoacid tablets (KA)
Number of subjects: 0
Study: 32128848

Group type: EXPERIMENTAL
Intervention: CBD (600 mg)
Number of subjects: 26
Study: 36164037

Group type: EXPERIMENTAL
Intervention: R-CHOP + tafasitamab (12 mg/kg IV, D1, 8, 15)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: R-CHOP + tafasitamab + lenalidomide (25 mg orally, D1-10)
Number of subjects: 130
Study: 33713329

Group type: EXPERIMENTAL
Intervention: Mini craniotomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Full-fledged craniotomy and endoscopy-guided surgery
Number of subjects: 0
Study: 32989825

Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid (50 mg/kg−1)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Systemic tranexamic acid (20 mg/kg−1 through cardiopulmonary bypass and another 20 mg/kg−1 after separation)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group (no antifibrinolytics)
Number of subjects: 117
Study: 35656757

Group type: COMPARATOR
Intervention: 0.5% Loteprednol etabonate (LE)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 0.1% Fluorometholone (FML)
Number of subjects: 100
Study: 34399759

Group type: EXPERIMENTAL
Intervention: iStent inject® + concurrent cataract surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cataract surgery alone
Number of subjects: 0
Study: 32464421

Group type: EXPERIMENTAL
Intervention: Moringa oleifera leaves extract (MOLE) at a dose of 40 mg/kg orally daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Vitamin E and selenium at a dose of 3 ml (4.5 mg sodium selenite and 204 mg vitamin E)/head i.m twice a week for 64 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Distilled water orally
Number of subjects: 24
Study: 36099091

Group type: EXPERIMENTAL
Intervention: HDR brachytherapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy volunteers (HV)
Number of subjects: 20
Study: 616835912

Group type: EXPERIMENTAL
Intervention: Eccentric strength training followed by task-oriented strength training (EST-TOST)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Task-oriented strength training followed by eccentric strength training (TOST-EST)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Eccentric strength training and task-oriented strength training
Number of subjects: 11
Study: 35112815

Group type: EXPERIMENTAL
Intervention: High-volume cluster sets (CLUS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lower-volume traditional sets (TRAD)
Number of subjects: 20
Study: 32472001

Group type: EXPERIMENTAL
Intervention: Olaparib tablets (300 mg twice daily)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Chemotherapy treatment of physician's choice (TPC)
Number of subjects: 87
Study: 36078247

Group type: EXPERIMENTAL
Intervention: Parent-Child Interaction Therapy (PCIT)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Services as Usual (SAU)
Number of subjects: 204
Study: 33532956

Group type: EXPERIMENTAL
Intervention: Diabetes Shared Medical Appointments (SMAs) totaling 8–9 hours
Number of subjects: 1537

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1537
Study: 35598114

Group type: EXPERIMENTAL
Intervention: Chloroquine alone (600 mg base)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Chloroquine with azithromycin (500 mg)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Chloroquine with azithromycin (1,000 mg)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Chloroquine with azithromycin (1,500 mg)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 33225343

Group type: EXPERIMENTAL
Intervention: Otago Exercise Program (n = 123)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Usual care (n = 133)
Number of subjects: 256
Study: 32614987

Group type: EXPERIMENTAL
Intervention: IncoA intradermal injection (100 unit or 1 vial in 6 cc of NSS)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: IncoA intradermal injection
Number of subjects: 22

Group type: COMPARATOR
Intervention: NSS
Number of subjects: 22
Study: 36036107

Group type: EXPERIMENTAL
Intervention: Thumbtack needling therapy
Number of subjects: 135

Group type: COMPARATOR
Intervention: Sham-thumbtack needling therapy
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 135

Group type: COMPARATOR
Intervention: Medication group (PCA)
Number of subjects: 135
Study: 33612607

Group type: EXPERIMENTAL
Intervention: Food habits (various dietary components assessed via structured questionnaire)
Number of subjects: 924

Group type: EXPERIMENTAL
Intervention: Food habits (specific habits assessed)
Number of subjects: 924

Group type: EXPERIMENTAL
Intervention: Eating dinner often
Number of subjects: 924

Group type: EXPERIMENTAL
Intervention: Having breakfast before school often
Number of subjects: 924

Group type: EXPERIMENTAL
Intervention: Eating cake or dessert at meal often
Number of subjects: 924

Group type: EXPERIMENTAL
Intervention: Drinking eight glasses of water often
Number of subjects: 924

Group type: EXPERIMENTAL
Intervention: Eating food from school canteen often
Number of subjects: 924

Group type: EXPERIMENTAL
Intervention: Bringing own snack from home often
Number of subjects: 924
Study: 34227956

Group type: EXPERIMENTAL
Intervention: Nurse-supported care
Number of subjects: 108

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 108
Study: 32423457

Group type: EXPERIMENTAL
Intervention: Universal test and treat (UTT) program
Number of subjects: 500

Group type: COMPARATOR
Intervention: Differed treatment program
Number of subjects: 500
Study: 36459357

Group type: EXPERIMENTAL
Intervention: Laparoscopic vertical clip gastroplasty (LVCG)
Number of subjects: 50
Study: 34688102

Group type: EXPERIMENTAL
Intervention: Project SAVE (30-min, web-based, single-session intervention)
Number of subjects: 565

Group type: COMPARATOR
Intervention: Active, attention-matched control program
Number of subjects: 565
Study: 35811299

Group type: EXPERIMENTAL
Intervention: Immersive virtual reality (VR) education
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional leaflets provided by asthma specialists (control group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both groups (VR and control)
Number of subjects: 30
Study: 33148686

Group type: EXPERIMENTAL
Intervention: Dextrose gel (buccal 40% dextrose gel)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Any dextrose
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Children who developed neonatal hypoglycaemia
Number of subjects: 360
Study: 32040014

Group type: EXPERIMENTAL
Intervention: CYD‐TDV (tetravalent dengue vaccine)
Number of subjects: 9740

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9740
Study: 36070590

Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT) with LED irradiation
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo group (LED-off)
Number of subjects: 14
Study: 33983111

Group type: EXPERIMENTAL
Intervention: Personalized interface/mask fitting session supervised by a certified sleep technician
Number of subjects: 156

Group type: COMPARATOR
Intervention: Usual care (obtaining an interface through durable medical equipment suppliers)
Number of subjects: 156
Study: 32559034

Group type: EXPERIMENTAL
Intervention: Particulate DBBM
Number of subjects: 17

Group type: COMPARATOR
Intervention: Block DBBM
Number of subjects: 17
Study: 35284687

Group type: EXPERIMENTAL
Intervention: HAZMAT workshop
Number of subjects: 100

Group type: COMPARATOR
Intervention: waitlist
Number of subjects: 100
Study: 33691183

Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 948

Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 948
Study: 36357085

Group type: EXPERIMENTAL
Intervention: TEER plus guideline-directed medical therapy (GDMT)
Number of subjects: 614

Group type: COMPARATOR
Intervention: GDMT alone
Number of subjects: 614
Study: 35716139

Group type: EXPERIMENTAL
Intervention: Self-sampling with HPV mRNA testing
Number of subjects: 5350

Group type: COMPARATOR
Intervention: Routine screening
Number of subjects: 5350
Study: 33390654

Group type: EXPERIMENTAL
Intervention: Inhaled glucocorticoids (fluticasone)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Oral glucocorticoids
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 9
Study: 36303867

Group type: EXPERIMENTAL
Intervention: Nomogram including variables such as radiotherapy, primary site surgery, Ann Arbor Stage, chemotherapy, histological subtype, and age at diagnosis.
Number of subjects: 1152

Group type: EXPERIMENTAL
Intervention: Nomogram for predicting 5-, 10-, and 15-year BC-PTML cancer-specific survival (CSS).
Number of subjects: 1152

Group type: COMPARATOR
Intervention: Traditional Ann Arbor staging system.
Number of subjects: 1152
Study: 34737091

Group type: EXPERIMENTAL
Intervention: Lofexidine (alpha-2 adrenergic agonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33620562

Group type: EXPERIMENTAL
Intervention: Nasotracheal intubation
Number of subjects: 108

Group type: COMPARATOR
Intervention: Orotracheal intubation
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: NRS score for sore throat on POD 1
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: NRS score for sore throat on POD 2
Number of subjects: 108
Study: 33216357

Group type: EXPERIMENTAL
Intervention: WhatsApp reminder (WR)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: WhatsApp reminder (WR) after crossover
Number of subjects: 500
Study: 36216309

Group type: EXPERIMENTAL
Intervention: Probiotics (109CFU of Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus paracasei and Bifidobacterium lactis)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 46
Study: 33533820

Group type: EXPERIMENTAL
Intervention: Early therapy (rehabilitative protocol started immediately after the initial evaluation)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Late therapy (rehabilitative protocol started 10 weeks later)
Number of subjects: 29
Study: 35886189

Group type: EXPERIMENTAL
Intervention: PPFF intervention (12 hr, 8 session)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) (50 hr, 25 session)
Number of subjects: 68
Study: 33318005

Group type: EXPERIMENTAL
Intervention: Ceftolozane-tazobactam
Number of subjects: 351

Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 351
Study: 32067249

Group type: EXPERIMENTAL
Intervention: AZD0284 (4-238 mg single dose or 12-100 mg multiple doses)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 33878856

Group type: EXPERIMENTAL
Intervention: Dupilumab (300 mg every 2 weeks) with concomitant topical corticosteroids
Number of subjects: 299
Study: 32920792

Group type: EXPERIMENTAL
Intervention: TTM risk score
Number of subjects: 100
Study: 35918313

Group type: EXPERIMENTAL
Intervention: Suvorexant (SUV); 10 mg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 32888746

Group type: EXPERIMENTAL
Intervention: Sensorimotor exercise program (thrice a week for 12 weeks)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 33